Plasmalogen augmentation reverses striatal dopamine loss in MPTP mice

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Miville Godbout, Edith ^a,b   Bourque, Mélanie ^a,b   Morissette, Marc ^a   Al Sweidi, Sara ^a   Smith, Tara ^c   Mochizuki, Asuka ^c,d   Senanayake, Vijitha ^c   Jayasinghe, Dushmanthi ^c   Wang, Li ^c   Goodenowe, Dayan ^c   Di Paolo, Thérèse ^a,b  

^a Université Laval   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c Phenomenome Discoveries Inc   (Canada)

^d CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOGENIC AMINE; DOCOSAHEXAENOIC ACID; DOPAMINE; DOPAMINE TRANSPORTER; ETHANOLAMINE DERIVATIVE; PLASMALOGEN; PPI 1011; SEROTONIN; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; VESICULAR MONOAMINE TRANSPORTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; MALE; MOUSE; MPTP-INDUCED PARKINSONISM; NONHUMAN; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; METABOLISM; PARKINSON DISEASE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOCOSAHEXAENOIC ACIDS; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; MALE; MICE; MICE, INBRED C57BL; PARKINSON DISEASE; PLASMALOGENS; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84962583837     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0151020     Document Type: Article

References (46)

1. Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease (2009). Neurology. 2009; 72(21 Suppl 4):S1-136. doi: 10.1212/WNL.0b013e3181a1d44c PMID: 19470958
2. Braverman NE, Moser AB. Functions of plasmalogen lipids in health and disease. Biochim Biophys Acta. 2012; 1822(9):1442-52. doi: 10.1016/j.bbadis.2012.05.008 PMID: 22627108
3. Bousquet M, Saint-Pierre M, Julien C, Salem N Jr, Cicchetti F, Calon F. Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinson's disease. FASEB J. 2008; 22(4):1213-25. fj.07-9677com [pii] doi: 10.1096/fj.07-9677com PMID: 18032633
4. Han X, Holtzman DM, McKeel DW Jr. Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry. J Neurochem. 2001; 77(4):1168-80. PMID: 11359882
5. Farooqui AA, Farooqui T, Horrocks LA. Metabolism and Functions of Bioactive Ether Lipids in the Brain. 1st ed. ed2008 april 13 2008. 260 p.
6. Dragonas C, Bertsch T, Sieber CC, Brosche T. Plasmalogens as a marker of elevated systemic oxidative stress in Parkinson's disease. Clin Chem Lab Med. 2009; 47(7):894-7. doi: 10.1515/CCLM.2009. 205 PMID: 19575554
7. Fabelo N, Martin V, Santpere G, Marin R, Torrent L, Ferrer I, et al. Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson's disease and incidental Parkinson's disease. Mol Med. 2011; 17(9-10):1107-18. doi: 10.2119/molmed.2011.00119 molmed.2011.00119 [pii] PMID: 21717034
8. Wood PL, Khan MA, Smith T, Ehrmantraut G, Jin W, Cui W, et al. In vitro and in vivo plasmalogen replacement evaluations in rhizomelic chrondrodysplasia punctata and Pelizaeus-Merzbacher disease using PPI-1011, an ether lipid plasmalogen precursor. Lipids Health Dis. 2011; 10:182. doi: 10.1186/ 1476-511X-10-182 PMID: 22008564
9. Wood PL, Smith T, Lane N, Khan MA, Ehrmantraut G, Goodenowe DB. Oral bioavailability of the ether lipid plasmalogen precursor, PPI-1011, in the rabbit: a new therapeutic strategy for Alzheimer's disease. Lipids Health Dis. 2011; 10:227. doi: 10.1186/1476-511X-10-227 1476-511X-10-227 [pii] PMID: 22142382
10. Bharat S, Cochran BC, Hsu M, Liu J, Ames BN, Andersen JK. Pre-treatment with R-lipoic acid alleviates the effects of GSH depletion in PC12 cells: implications for Parkinson's disease therapy. Neurotoxicology. 2002; 23(4-5):479-86. PMID: 12428720
11. Karunakaran S, Diwakar L, Saeed U, Agarwal V, Ramakrishnan S, Iyengar S, et al. Activation of apoptosis signal regulating kinase 1 (ASK1) and translocation of death-associated protein, Daxx, in substantia nigra pars compacta in a mouse model of Parkinson's disease: protection by alpha-lipoic acid. FASEB J. 2007; 21(9):2226-36. fj.06-7580com [pii] doi: 10.1096/fj.06-7580com PMID: 17369508
12. Blandini F, Armentero MT. Animal models of Parkinson's disease. FEBS J. 2012; 279(7):1156-66. doi: 10.1111/j.1742-4658.2012.08491.x PMID: 22251459
13. Davis GC, Williams AC, Markey SP, Ebert MH, Caine ED, Reichert CM, et al. Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res. 1979; 1(3):249-54. PMID: 298352
14. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983; 219(4587):979-80. PMID: 6823561
15. Tieu K. A guide to neurotoxic animal models of Parkinson's disease. Cold Spring Harb Perspect Med. 2011; 1(1):a009316. doi: 10.1101/cshperspect.a009316 PMID: 22229125
16. Bove J, Perier C. Neurotoxin-based models of Parkinson's disease. Neuroscience. 2012; 211:51-76. doi: 10.1016/j.neuroscience.2011.10.057 PMID: 22108613
17. Bourque M, Morissette M, Di Paolo T. Raloxifene activates G protein-coupled estrogen receptor 1/Akt signaling to protect dopamine neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice. Neurobiol Aging. 2014; 35(10):2347-56. doi: 10.1016/j.neurobiolaging.2014.03.017 PMID: 24726471
18. Ruffoli R, Giambelluca MA, Scavuzzo MC, Pasquali L, Giannessi F, Fornai F. MPTP-induced Parkinsonism is associated with damage to Leydig cells and testosterone loss. Brain Res. 2008; 1229:218-23. doi: 10.1016/j.brainres.2008.06.116 PMID: 18644355
19. Cote M, Bourque M, Poirier AA, Aube B, Morissette M, Di Paolo T, et al. GPER1-mediated immunomodulation and neuroprotection in the myenteric plexus of a mouse model of Parkinson's disease. Neurobiol Dis. 2015; 82:99-113. doi: 10.1016/j.nbd.2015.05.017 PMID: 26051538
20. Bourque M, Dluzen DE, Di Paolo T. Signaling pathways mediating the neuroprotective effects of sex steroids and SERMs in Parkinson's disease. Front Neuroendocrinol. 2012; 33(2):169-78. doi: 10.1016/ j.yfrne.2012.02.003 PMID: 22387674
21. Bourque M, Morissette M, Cote M, Soulet D, Di Paolo T. Implication of GPER1 in neuroprotection in a mouse model of Parkinson's disease. Neurobiol Aging. 2013; 34(3):887-901. doi: 10.1016/j. neurobiolaging.2012.05.022 PMID: 22749492
22. Litim N, Bourque M, Al Sweidi S, Morissette M, Di Paolo T. The 5alpha-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson's disease. Neuropharmacology. 2015; 97:86-94. doi: 10.1016/j.neuropharm.2015.05.015 PMID: 26006269
23. Franklin KBJ, Paxinos G. The Mouse Brain in Stereotaxic Coordinates. San Diego: Academic Press; 1997.
24. Grandbois M, Morissette M, Callier S, Di Paolo T. Ovarian steroids and raloxifene prevent MPTPinduced dopamine depletion in mice. Neuroreport. 2000; 11(2):343-6. PMID: 10674483
25. Callier S, Morissette M, Grandbois M, Pelaprat D, Di Paolo T. Neuroprotective properties of 17betaestradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice. Synapse. 2001; 41(2):131-8. doi: 10. 1002/syn.1067 [pii] 10.1002/syn.1067 PMID: 11400179
26. Kilbourn M, Frey K. Striatal concentrations of vesicular monoamine transporters are identical in MPTPsensitive (C57BL/6) and-insensitive (CD-1) mouse strains. Eur J Pharmacol. 1996; 307(2):227-32. 0014-2999(96)00252-X [pii] PMID: 8832225
27. Mankidy R, Ahiahonu PW, Ma H, Jayasinghe D, Ritchie SA, Khan MA, et al. Membrane plasmalogen composition and cellular cholesterol regulation: a structure activity study. Lipids Health Dis. 2010; 9:62. doi: 10.1186/1476-511X-9-62 PMID: 20546600
28. Ginsberg L, Rafique S, Xuereb JH, Rapoport SI, Gershfeld NL. Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer's disease brain. Brain Res. 1995; 698(1-2):223-6. 0006-8993(95)00931-F [pii] PMID: 8581486
29. Agid Y, Cervera P, Hirsch E, Javoy-Agid F, Lehericy S, Raisman R, et al. Biochemistry of Parkinson's disease 28 years later: a critical review. Mov Disord. 1989; 4 Suppl 1:S126-44. PMID: 2566912
30. Hornykiewicz O. Brain monoamines and parkinsonism. Natl Inst Drug Abuse Res Monogr Ser. 1975;(3: ):13-21. PMID: 787796
31. Kish SJ, Tong J, Hornykiewicz O, Rajput A, Chang LJ, Guttman M, et al. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain. 2008; 131(Pt 1):120-31. doi: 10. 1093/brain/awm239 PMID: 17956909
32. Bomasang-Layno E, Fadlon I, Murray AN, Himelhoch S. Antidepressive treatments for Parkinson's disease: A systematic review and meta-analysis. Parkinsonism Relat Disord. 2015; 21(8):833-42. doi: 10. 1016/j.parkreldis.2015.04.018 PMID: 26037457
33. Stenvinkel P, Diczfalusy U, Lindholm B, Heimburger O. Phospholipid plasmalogen, a surrogate marker of oxidative stress, is associated with increased cardiovascular mortality in patients on renal replacement therapy. Nephrol Dial Transplant. 2004; 19(4):972-6. doi: 10.1093/ndt/gfh035 PMID: 15031358
34. Yoshihara S, Harada K, Ohta S. Metabolism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in perfused rat liver: involvement of hepatic aldehyde oxidase as a detoxification enzyme. Drug Metab Dispos. 2000; 28(5):538-43. PMID: 10772632
35. Nishimukai M, Maeba R, Yamazaki Y, Nezu T, Sakurai T, Takahashi Y, et al. Serum choline plasmalogens, particularly those with oleic acid in sn-2, are associated with proatherogenic state. J Lipid Res. 2014; 55(5):956-65. doi: 10.1194/jlr.P045591 PMID: 24616482
36. Cartier EA, Parra LA, Baust TB, Quiroz M, Salazar G, Faundez V, et al. A biochemical and functional protein complex involving dopamine synthesis and transport into synaptic vesicles. J Biol Chem. 2010; 285(3):1957-66. doi: 10.1074/jbc.M109.054510 PMID: 19903816
37. Munn NJ, Arnio E, Liu D, Zoeller RA, Liscum L. Deficiency in ethanolamine plasmalogen leads to altered cholesterol transport. J Lipid Res. 2003; 44(1):182-92. PMID: 12518037
38. Wood PL, Khan MA, Smith T, Goodenowe DB. Cellular diamine levels in cancer chemoprevention: modulation by ibuprofen and membrane plasmalogens. Lipids Health Dis. 2011; 10:214. doi: 10.1186/ 1476-511X-10-214 PMID: 22087745
39. Perichon R, Moser AB, Wallace WC, Cunningham SC, Roth GS, Moser HW. Peroxisomal disease cell lines with cellular plasmalogen deficiency have impaired muscarinic cholinergic signal transduction activity and amyloid precursor protein secretion. Biochem Biophys Res Commun. 1998; 248(1):57-61. doi: 10.1006/bbrc.1998.8909 PMID: 9675085
40. Styger R, Wiesmann UN, Honegger UE. Plasmalogen content and beta-adrenoceptor signalling in fibroblasts from patients with Zellweger syndrome. Effects of hexadecylglycerol. Biochim Biophys Acta. 2002; 1585(1):39-43. PMID: 12457713
41. Vartanian T, Sprinkle TJ, Dawson G, Szuchet S. Oligodendrocyte substratum adhesion modulates expression of adenylate cyclase-linked receptors. Proc Natl Acad Sci USA. 1988; 85(3):939-43. PMID: 2448785
42. Jones KT, Zhen J, Reith ME. Importance of cholesterol in dopamine transporter function. J Neurochem. 2012; 123(5):700-15. doi: 10.1111/jnc.12007 PMID: 22957537
43. Hossain MS, Ifuku M, Take S, Kawamura J, Miake K, Katafuchi T. Plasmalogens rescue neuronal cell death through an activation of AKT and ERK survival signaling. PLoS One. 2013; 8(12):e83508. doi: 10.1371/journal.pone.0083508 PONE-D-13-33206 [pii] PMID: 24376709
44. D'Astous M, Mendez P, Morissette M, Garcia-Segura LM, Di Paolo T. Implication of the phosphatidylinositol-3 kinase/protein kinase B signaling pathway in the neuroprotective effect of estradiol in the striatum of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice. Mol Pharmacol. 2006; 69(4):1492-8. doi: 10.1124/mol.105.018671 PMID: 16434614
45. Youdim MB, Kupershmidt L, Amit T, Weinreb O. Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson's disease. Parkinsonism Relat Disord. 2014; 20 Suppl 1:S132-6. doi: 10.1016/S1353-8020(13)70032-4 PMID: 24262165
46. Zhao Q, Cai D, Bai Y. Selegiline rescues gait deficits and the loss of dopaminergic neurons in a subacute MPTP mouse model of Parkinson's disease. Int J Mol Med. 2013; 32(4):883-91. doi: 10.3892/ ijmm.2013.1450 PMID: 23877198